Trial Profile

A Multicenter, Open Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of LBL-033 in the Treatment of Patients With Advanced Malignant Tumors.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 15 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Jun 2023 According to Nanjing Leads Biolabs media release, FDA (U.S. Food and Drug Administration) has approved the clinical trial application of LBL-033 in the United States for the treatment of ovarian cancer and other malignant tumors.
16 Jun 2023 According to Nanjing Leads Biolabs media release, IND approval for clinical trial was granted by the NMPA (National Medical Products Administration) in China on 16 Feb, 2023 and on 27 Apr, 2023, the first participant has been successfully dosed at Sun Yat-sen University Cancer Center.
05 Jun 2023 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com